ARTICLE
5 August 2014

ESMA Consults On The Calculation Of Counterparty Risk By UCITS

AO
A&O Shearman

Contributor

A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets. This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world. A firm that advises at the forefront of the forces changing the current of global business and that is unrivalled in its global strength. Our clients benefit from the collective experience of teams who work with many of the world’s most influential companies and institutions, and have a history of precedent-setting innovations. Together our lawyers advise more than a third of NYSE-listed businesses, a fifth of the NASDAQ and a notable proportion of the London Stock Exchange, the Euronext, Euronext Paris and the Tokyo and Hong Kong Stock Exchanges.
ESMA published a discussion paper seeking comments on its proposals for the calculation of counterparty risk by UCITS for OTC derivative transactions.
European Union Finance and Banking

On 22 July 2014, the European Securities and Markets Authority ("ESMA") published a discussion paper seeking comments on its proposals for the calculation of counterparty risk by Undertakings for Collective Investment in Transferable Securities ("UCITS") for OTC derivative transactions subject to the clearing obligation under the European Market Infrastructure Regulation ("EMIR"). ESMA is concerned about the impact of a failing clearing member, or client of a clearing member, on a UCITS entering cleared OTC derivatives. UCITS are retail investment funds and are regulated across the EU to ensure investor protection. ESMA is seeking views on: (i) how a UCITS should calculate limits on counterparty risk in centrally cleared OTC derivative transactions; and (ii) whether the same rules should be applied by a UCITS for centrally cleared OTC transactions as for exchange-traded derivatives ("ETDs"). Under existing UCITS legislation, a UCITS' investments in OTC derivatives are subject to counterparty risk exposure limits. ETDs are not subject to the same limitation. The discussion paper is open until 22 October 2014.

The ESMA discussion paper is available at: http://www.esma.europa.eu/news/ESMA-consults-counterparty-risk-calculation-methods-UCITS-subject-central-clearing?t=326&o=home

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More